KAT6B is a tumor suppressor histone H3 lysine 23 acetyltransferase undergoing genomic loss in small cell lung cancer

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3936-3944

  Simó Riudalbas, Laia ^a   Pérez Salvia, Montserrat ^a   Setien, Fernando ^a   Villanueva, Alberto ^b   Moutinho, Catia ^a   Martínez Cardús, Anna ^a   Moran, Sebastian ^a   Berdasco, Maria ^a   Gomez, Antonio ^a   Vidal, Enrique ^a   Soler, Marta ^a   Heyn, Holger ^a   Vaquero, Alejandro ^a   De La Torre, Carolina ^a   Barceló Batllori, Silvia ^a   Vidal, August ^c   Roz, Luca ^d   Pastorino, Ugo ^d   Szakszon, Katalin ^e   Borck, Guntram ^f   Moura, Conceição S ^g   Carneiro, Fátima ^h   Zondervan, Ilse ⁱ   Savola, Suvi ⁱ   Iwakawa, Reika ^j   Kohno, Takashi ^j   Yokota, Jun ^j,k   Esteller, Manel ^a,l,m   more..

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f UNIVERSITY OF ULM   (Germany)

^g Centro Hospitalar Universitário de São João   (Portugal)

^h University of Porto   (Portugal)

ⁱ MRC HOLLAND   (Netherlands)

^j NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^k Institute of Predictive and Personalized Medicine of Cancer (IMPPC)   (Spain)

^l UNIVERSITY OF BARCELONA   (Spain)

^m INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; HISTONE ACETYLTRANSFERASE KAT6B; HISTONE H3; LYSINE; LYSINE 23; PROTEIN; UNCLASSIFIED DRUG; ALKYLATING AGENT; CAMPTOTHECIN; HISTONE; HISTONE ACETYLTRANSFERASE; IRINOTECAN; KAT6B PROTEIN, HUMAN; MESSENGER RNA; RNA; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; ENZYME ACTIVITY; EPIGENETICS; GENE DELETION; GENE MUTATION; GENOTYPE; HISTONE ACETYLATION; HOMOZYGOSITY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; TUMOR SUPPRESSOR GENE; ACETYLATION; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, SMALL CELL; CHROMATIN IMMUNOPRECIPITATION; DEFICIENCY; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; GENE DELETION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 84943163571     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3702     Document Type: Article

References (47)

1. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-55.
2. Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol 2014;41:133-42.
3. Buettner R, Wolfm J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013;31:1858-65.
4. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
5. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
6. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6.
7. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010;19:698-711.
8. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
9. Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, Moran S, et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 2014;33:2807-13.
10. Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005;11:512-9.
11. Champagne N, Bertos NR, Pelletier N, Wang AH, Vezmar M, Yang Y, et al. Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. J Biol Chem 1999;274:28528-36.
12. Yang XJ, Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 2007;26:5408-19.
13. Klein BJ, Lalonde ME, Côté J, Yangm X J, Kutateladze TG. Crosstalkbetween epigenetic readers regulates the MOZ/MORF HAT complexes. Epigenetics 2014;9:186-93.
14. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, et al. Mutational analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998;17:1557-65.
15. Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billstrom R, Strombeck B, et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t (10;16) (q22;p13). Hum Mol Genet 2001;10:395-404.
16. Vizmanos JL, Larráyoz MJ, Lahortiga I, Floristán F, Alvarez C, Odero MD, et al. t (10;16) (q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia. Genes Chromosomes Cancer 2003;36:402-5.
17. Moore SD, Herrick SR, Ince TA, Kleinman MS, Dal Cin P, Morton CC, et al. Uterine leiomyomata with t (10;17) disrupt the histone acetyltransferase MORF. Cancer Res 2004;64:5570-7.
18. Clayton-Smith J, O'Sullivan J, Daly S, Bhaskar S, Day R, Anderson B, et al. Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome. Am J Hum Genet 2011;89:675-81.
19. Campeau PM, Kim JC, Lu JT, Schwartzentruber JA, Abdul-Rahman OA, Schlaubitz S, et al. Mutations in KAT6B, encoding a histone acetyltransferase, cause Genitopatellar syndrome. Am J Hum Genet 2012;90:282-9.
20. Simpson MA, Deshpande C, Dafou D, Vissers LE, Woollard WJ, Holder SE, et al. De novo mutations of the gene encoding the histone acetyltransferase KAT6B cause Genito patellar syndrome. Am J Hum Genet 2012;90:290-4.
21. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
22. Kahali B, Gramling SJ, Marquez SB, Thompson K, Lu L, Reisman D. Identifying targets for the restoration and reactivation of BRM. Oncogene 2014;33:653-64.
23. Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, et al. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 2005;65:3542-7.
24. Voss AK, Collin C, Dixon MP, Thomas T. Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. Dev Cell 2009;17:674-86.
25. Qiu Y, Liu L, Zhao C, Han C, Li F, Zhang J, et al. Combinatorial readout of unmodified H3R2 and acetylated H3K14 by the tandem PHD finger of MOZ reveals a regulatory mechanism for HOXA9 transcription. Genes Dev 2012;26:1376-91.
26. Dreveny I, Deeves SE, Fulton J, Yue B, Messmer M, Bhattacharya A, etal. The double PHD finger domain of MOZ/MYST3 induces α-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification. Nucl Acids Res 2014;42:822-35.
27. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. The translocation t (8;16) (p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996;14:33-41.
28. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with at (8;22) (p11;q13) chromosome translocation. Leukemia 2001;15:89-94.
29. Doyon Y, Cayrou C, Ullah M, Landry AJ, Côte AV, Selleck W, etal. INGtumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006;21:51-64.
30. Ali M, Yan K, Lalonde ME, Degerny C, Rothbart SB, Strahl BD, et al. Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin. J Mol Biol 2012;424:328-38.
31. Szakszon K, Berényi E, Jakab A, Bessenyei B, Balogh E, Köbling T, et al. Blepharophimosis mental retardation syndrome Say-Barber/Biesecker/Young-Simpson type-new findings with neuroimaging. Am J Med Genet A 2011;155A:634-7.
32. Szakszon K, Salpietro C, Kakar N, Knegt AC, Oláh É, Dallapiccola B, et al. De novo mutations of the gene encoding the histone acetyltransferase KAT6B in two patients with Say-Barber/Biesecker/Young-Simpson syndrome. Am J Med Genet A 2013;161A:884-8.
33. Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A, etal. hMOFhistone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol 2005;25:6798-810.
34. Smith ER, Cayrou C, Huang R, Lane WS, Côté J, Lucchesi JC, et al. A human protein complex homologous to the Drosophila MSL complex is responsible forthe majority of histone H4 acetylation at lysine 16. Mol Cell Biol 2005;25:9175-88.
35. Yuan H, Rossetto D, Mellert H, Dang W, Srinivasan M, Johnson J, et al. MYST protein acetyltransferase activity requires active site lysine autoacetylation. EMBO J 2012;31:58-70.
36. Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer 2013;52:802-16.
37. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cellsby apotent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65.
38. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
39. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
40. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
41. Vonlaufen N, Naguleswaran A, Coppens I, Sullivan WJ Jr. MYST family lysine acetyltransferase facilitates ataxia telangiectasia mutated (ATM) kinase-mediated DNA damage response in Toxoplasma gondii. J Biol Chem 2010;285:11154-61.
42. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e400S-19S.
43. Kebede AF, Schneider R, Daujat S. Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest. FEBS J 2015;282:1658-74.
44. Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta 2014;1839:627-43.
45. Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, Nakatani Y, et al. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J Biol Chem 1999;274:1189-92.
46. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 2014;20:1394-6.
47. Papazyan R, Voronina E, Chapman JR, Luperchio TR, Gilbert TM, Meier E, et al. Methylation of histone H3K23 blocks DNA damage in pericentric heterochromatin during meiosis. Elife 2014;3:e02996.